KTN3379: Interim Phase I data

Interim data from 36 patients with advanced solid tumors in a 2-part, open-label, U.S. Phase Ib trial showed that KTN3379 alone and in combination with Erbitux cetuximab, Zelboraf vemurafenib or He...